- Home
- AKA vs ELTX Comparison
AKA vs ELTX Comparison
Compare AKA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- ELTX
- Stock Information
- Founded
- AKA 2018
- ELTX 2011
- Country
- AKA United States
- ELTX United States
- Employees
- AKA N/A
- ELTX N/A
- Industry
- AKA Catalog/Specialty Distribution
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- ELTX Health Care
- Exchange
- AKA Nasdaq
- ELTX Nasdaq
- Market Cap
- AKA 110.4M
- ELTX 121.7M
- IPO Year
- AKA 2021
- ELTX N/A
- Fundamental
- Price
- AKA $10.01
- ELTX $11.70
- Analyst Decision
- AKA Strong Buy
- ELTX Strong Buy
- Analyst Count
- AKA 3
- ELTX 2
- Target Price
- AKA $24.33
- ELTX $11.00
- AVG Volume (30 Days)
- AKA 5.4K
- ELTX 158.3K
- Earning Date
- AKA 11-06-2025
- ELTX 08-07-2025
- Dividend Yield
- AKA N/A
- ELTX N/A
- EPS Growth
- AKA N/A
- ELTX N/A
- EPS
- AKA N/A
- ELTX N/A
- Revenue
- AKA $598,107,000.00
- ELTX N/A
- Revenue This Year
- AKA $7.23
- ELTX N/A
- Revenue Next Year
- AKA $4.04
- ELTX N/A
- P/E Ratio
- AKA N/A
- ELTX N/A
- Revenue Growth
- AKA 7.67
- ELTX N/A
- 52 Week Low
- AKA $7.00
- ELTX $3.91
- 52 Week High
- AKA $32.25
- ELTX $12.42
- Technical
- Relative Strength Index (RSI)
- AKA 37.66
- ELTX 64.86
- Support Level
- AKA $10.42
- ELTX $10.01
- Resistance Level
- AKA $10.99
- ELTX $12.13
- Average True Range (ATR)
- AKA 0.44
- ELTX 0.63
- MACD
- AKA -0.06
- ELTX 0.01
- Stochastic Oscillator
- AKA 0.00
- ELTX 75.74
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.